0HI3 주식 개요 는 미국에서 난치성 질환 치료를 위한 의약품을 개발하는 회사입니다. 자세한 내용
보상 위험 분석 + 1 더 많은 위험
모든 위험 점검 보기 생각, 링크 및 회사 내러티브를 캡처하세요.
메모 추가Arrowhead Pharmaceuticals, Inc. 경쟁사 가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 Arrowhead Pharmaceuticals 과거 주가 현재 주가 US$19.60 52주 최고치 US$39.79 52주 최저치 US$17.24 베타 0.93 1개월 변경 2.48% 3개월 변경 사항 2.44% 1년 변경 사항 -36.59% 3년 변화 -70.45% 5년 변화 -69.65% IPO 이후 변화 220.22%
최근 뉴스 및 업데이트
Arrowhead Pharmaceuticals, Inc. Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity Dec 24
CEO, President & Director recently sold US$567k worth of stock Dec 22
Arrowhead Pharmaceuticals, Inc. Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases Dec 11
Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2A Study of ARO-ALK7 for the Treatment of Obesity Dec 03
New minor risk - Revenue size Nov 27
Full year 2024 earnings released: US$4.82 loss per share (vs US$1.92 loss in FY 2023) Nov 27 더 많은 업데이트 보기
Arrowhead Pharmaceuticals, Inc. Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity Dec 24
CEO, President & Director recently sold US$567k worth of stock Dec 22
Arrowhead Pharmaceuticals, Inc. Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases Dec 11
Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2A Study of ARO-ALK7 for the Treatment of Obesity Dec 03
New minor risk - Revenue size Nov 27
Full year 2024 earnings released: US$4.82 loss per share (vs US$1.92 loss in FY 2023) Nov 27
Arrowhead Pharmaceuticals, Inc. Appoints Doug Ingram to the Board of Directors Nov 26 Arrowhead Pharmaceuticals, Inc. Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
New major risk - Financial position Sep 05
Arrowhead Pharmaceuticals, Inc. Presents New Pivotal Phase 3 Data At ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome Sep 03
Arrowhead Pharmaceuticals, Inc. to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, into Clinical Studies Aug 15
New minor risk - Financial position Aug 09
Third quarter 2024 earnings released: US$1.38 loss per share (vs US$0.96 loss in 3Q 2023) Aug 09
Arrowhead Pharmaceuticals to Advance RNAi-Based Plozasiran into Phase 3 Capitan Cardiovascular Outcomes Trial Jun 26
Arrowhead Pharmaceuticals, Inc. Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 Palisade Study in Patients with Familial Chylomicronemia Syndrome Jun 05
Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma May 22
Now 22% undervalued after recent price drop May 11
Second quarter 2024 earnings released: US$1.04 loss per share (vs US$0.46 profit in 2Q 2023) May 10
Now 23% undervalued after recent price drop Apr 24
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease Apr 24
Arrowhead Pharmaceuticals, Inc. Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo Apr 09
Chief Financial Officer recently sold US$1.4m worth of stock Mar 11
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy Mar 08
Now 27% overvalued after recent price rise Mar 01
First quarter 2024 earnings released: US$1.24 loss per share (vs US$0.39 loss in 1Q 2023) Feb 07
Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 14, 2024 Jan 27
Arrowhead Pharmaceuticals, Inc. Announces Leaving of Javier San Martin, M.D., as the Chief Medical Officer, Effective from February 1, 2024 Jan 22
Arrowhead Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $450.015 million. Jan 05
New major risk - Financial position Dec 06
New major risk - Financial position Nov 30
Full year 2023 earnings released: US$1.92 loss per share (vs US$1.67 loss in FY 2022) Nov 30
Arrowhead Pharmaceuticals, Inc. Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy Nov 29
Chief Medical Officer recently sold US$567k worth of stock Nov 23
Arrowhead Pharmaceuticals Inc. Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023 Nov 15
New minor risk - Share price stability Oct 05
New major risk - Revenue and earnings growth Sep 23
Third quarter 2023 earnings released: US$0.96 loss per share (vs US$0.68 loss in 3Q 2022) Aug 08
New minor risk - Insider selling Jul 03
Chief Financial Officer recently sold US$543k worth of stock Jul 02
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate A Phase 1 Study of Aro-Sod1 Jun 28
Chairman of the Board recently sold US$266k worth of stock May 10 May 03
Second quarter 2023 earnings released: EPS: US$0.46 (vs US$0.42 in 2Q 2022) May 03 Arrowhead Pharmaceuticals, Inc. Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 Results
First quarter 2023 earnings released: US$0.39 loss per share (vs US$0.60 loss in 1Q 2022) Feb 07
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-Mmp7 for Treatment of Idiopathic Pulmonary Fibrosis Feb 03
Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 16, 2023 Jan 31
Arrowhead Pharmaceuticals, Inc. (NasdaqGS:ARWR) acquired unknown majority stake in Visirna Therapeutics. Jan 22
Arrowhead Pharmaceuticals Inc. and Takeda Pharmaceutical Company Limited Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease Jan 10
Insufficient new directors Jan 01
Arrowhead Pharmaceuticals Inc. to Present Topline Data from the Phase 2 SEQUOIA Study Evaluating Fazirsiran and Describe Design for Planned Phase 3 Study Dec 22
No longer forecast to breakeven Dec 01
Arrowhead Presents New Phase 2 Data At AHA 2022 on Cardiometabolic Pipeline Nov 08
Arrowhead Pharmaceuticals to Present Interim Phase 2 Clinical Data At AHA 2022 on SHASTA-2 Study of ARO-APOC3 and Arches-2 Study of ARO-ANG3 Oct 12
Third quarter 2022 earnings released: US$0.68 loss per share (vs US$0.29 loss in 3Q 2021) Aug 05
Arrowhead Pharmaceuticals, Inc. Appoints Patrick O’Brien as Chief Operating Officer Jul 21
Arrowhead Pharmaceuticals Inc. Initiates Phase 1/2a Studies for Two Pulmonary Candidates ARO-MUC5AC and ARO-RAGE Jul 06
Takeda and Arrowhead Announce Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine Jun 28
Second quarter 2022 earnings released: EPS: US$0.41 (vs US$0.26 loss in 2Q 2021) May 11
Arrowhead Pharmaceuticals, Inc. Appoints Victoria Vakiener to Board of Directors May 03
Arrowhead Pharmaceuticals Inc. Doses the First Patients in the Phase 2 GATEWAY Clinical Study of Investigational ARO-ANG3 for the Treatment of Patients with Homozygous Familial Hypercholesterolemia Apr 27
Arrowhead Pharmaceuticals Inc. Completes Enrollment in Phase 2b ARCHES-2 Study of Investigational ARO-ANG3 for Patients with Mixed Dyslipidemia Feb 25
Arrowhead Pharmaceuticals, Inc. Initiates Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases Feb 19
Arrowhead Pharmaceuticals, Inc. Presents New Clinical Data on ARO-HIF2 at ASCO GU 2022 Feb 18
First quarter 2022 earnings: EPS in line with expectations, revenues disappoint Feb 04
Arrowhead Pharmaceuticals Inc Initiates Phase 3 PALISADE Study of ARO-APOC3 for Treatment of Familial Chylomicronemia Syndrome Jan 13
Independent Director recently sold US$291k worth of stock Jan 06
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Nov 23
Chairman of the Board recently sold US$326k worth of stock Sep 14
Chief Commercial Officer James Hassard has left the company Sep 02
Third quarter 2021 earnings released: US$0.29 loss per share (vs US$0.13 loss in 3Q 2020) Aug 08
Arrowhead Pharmaceuticals, Inc. Pauses ARO-ENaC Phase 1/2 Clinical Study Jul 03
Arrowhead Pharmaceuticals, Inc. Initiates Phase 2B Study of Investigational ARO-ANG3 for Treatment of Mixed Dyslipidemia Jul 01
Arrowhead Presents Preclinical Data on ARO-DUX4 at FSHD Society International Research Congress Jun 26
Chief Commercial Officer recently sold US$323k worth of stock Jun 25
Arrowhead Pharmaceuticals, Inc. Presents Positive Interim Clinical Data on ARO-HSD Treatment in Patients with Suspected NASH At EASL International Liver Congress Jun 24
Arrowhead Pharmaceuticals Initiates Phase 2b Study of Investigational ARO-APOC3 for Treatment of Severe Hypertriglyceridemia Jun 04
Second quarter 2021 earnings released: US$0.26 loss per share (vs US$0.20 loss in 2Q 2020) May 06
Arrowhead Pharmaceuticals Inc. Announces Improvement in Fibrosis after ARO-AAT Treatment in Patients with Alpha-1 Liver Disease Apr 29
Arrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe Hypertriglyceridemia Mar 03
Chairman of the Board recently sold US$100k worth of stock Feb 27
First quarter 2021 earnings released: US$0.20 loss per share (vs US$0.028 loss in 1Q 2020) Feb 06
Revenue misses expectations Feb 06
Arrowhead Pharmaceuticals Files IND for Phase 2b Study of ARO-ANG3 for Treatment of Mixed Dyslipidemia Jan 26
Chief Financial Officer recently sold US$1.1m worth of stock Jan 20
Chairman of the Board recently sold US$759k worth of stock Dec 22 주주 수익률 0HI3 GB Biotechs GB 마켓 7D -9.6% -1.0% -0.6% 1Y -36.6% -24.1% 3.1%
전체 주주 수익률 보기
수익률 대 산업: 0HI3 지난 1년 동안 -24.1 %를 반환한 UK Biotechs 업계보다 저조한 성과를 냈습니다.
수익률 대 시장: 0HI3 지난 1년 동안 3.1 %를 반환한 UK 시장보다 저조한 성과를 냈습니다.
가격 변동성 Is 0HI3's price volatile compared to industry and market? 0HI3 volatility 0HI3 Average Weekly Movement 10.4% Biotechs Industry Average Movement 7.0% Market Average Movement 4.8% 10% most volatile stocks in GB Market 10.6% 10% least volatile stocks in GB Market 2.6%
안정적인 주가: 0HI3 의 주가는 지난 3개월 동안 변동성이 심했습니다.
시간에 따른 변동성: 0HI3 의 주간 변동성 ( 10% )은 지난 1년 동안 안정적이었지만 여전히 UK 의 75%보다 높습니다. 주식.
회사 소개 는 미국에서 난치성 질환 치료를 위한 의약품을 개발하는 회사입니다. 이 회사의 제품 파이프라인에는 고중성지방혈증, 이상지질혈증, 가족성 킬로미크론혈증 증후군 치료를 위한 임상 3상 시험을 완료한 플로자시란, 아포지단백 A 생산을 감소시키는 임상 3상 시험 중인 올파시란, 알파-1 항트립신 결핍과 관련된 간 질환 치료를 위한 임상 3상 시험 중인 파지르시란이 있습니다. 또한 이상지질혈증 및 고중성지방혈증 치료를 위해 임상 2b상 중인 조다시란, 대사 기능 장애 관련 지방간염(MASH) 치료를 위한 GSK-4532990, 만성 B형 간염 치료를 위해 임상 2상 중인 다플루시란/톰리지시란을 개발 중입니다.
자세히 보기 Arrowhead Pharmaceuticals, Inc. 기본 사항 요약 Arrowhead Pharmaceuticals 의 수익과 매출은 시가총액과 어떻게 비교하나요? 0HI3 기본 통계 시가총액 US$2.44b 수익(TTM ) -US$599.49m 수익(TTM ) US$3.55m
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) 0HI3 손익 계산서(TTM ) 수익 US$3.55m 수익 비용 US$0 총 이익 US$3.55m 기타 비용 US$603.04m 수익 -US$599.49m
주당 순이익(EPS) -4.82 총 마진 100.00% 순이익 마진 -16,882.37% 부채/자본 비율 384.5%
0HI3 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기
기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2024/12/25 13:09 장 마감 주가 2024/12/24 00:00 수익 2024/09/30 연간 수익 2024/09/30
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.
애널리스트 출처 Arrowhead Pharmaceuticals, Inc. 29 애널리스트 중 16 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
분석가 교육기관 Ishan Majumdar Baptista Research Ying Huang Barclays Jason Matthew Gerberry BofA Global Research
26 더 많은 분석가 보기